![]() |
Amily |
![]() |
Emily |
![]() |
Lily |
武汉科斯坦生物科技有限公司
-
在线咨询
-
官方邮箱
-
微信下单
-
回到顶部
代谢组学
科研服务
抗体/蛋白
地 址:武汉市东湖新技术开发区高新大道666号,武汉
国家生物产业基地B、C、D区研发楼C1栋
产品销售:15926423062
技术服务:18971263062
E - mail :info@chemstan.com
邮 编:430075
化合物单体
科斯坦生物(Chemstan)所有产品和服务仅用于科学研究,不为任何个人或者非科研性质的用途提供产品和服务。
Copyright @ 武汉科斯坦生物科技有限公司.All rights reserved
网站建设:中企动力武汉鄂ICP备19006850号-1
浏览量:
产品名称:
Research Grade Ravulizumab ( 雷夫利珠单抗 )
NO.
444
货号:
CSD00472
中文名称
雷夫利珠单抗
英文名词
Research Grade Ravulizumab
CAS号
1803171-55-2
产品货号:
CSD00472
货期:
现货
价格与订购:
2480.00
数量:
-
+
库存:
100
产品信息
如何订购
货号(Catalog No.)icon
CSD00472
通用名INNicon
Ravulizumab
纯度(Purity)icon
>95%
浓度( Concentration)icon
1mg/ml
Formulationicon
PBS buffer PH7.5
Sourceicon
CHO cells
内毒素(Endotoxin level)icon
Please contact with the lab for this information.
产品描述(Description)icon
Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.
别名(Alternative names)icon
ALXN-1210,ravulizumab-cwvz
靶点;物种(Specificity target name;species)icon
C5[Homo sapiens]
种类(Species)icon
Humanized
受体鉴定(Receptor identification)icon
IgG2-G4-kappa
CASicon
1803171-55-2
存储条件(Storage)icon
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Noteicon
For research use only .
上一篇
Research Grade Crizanlizumab ( 立赞利珠单抗 )
Research Grade Tomaralimab (托拉利单抗 )
下一篇